Scheidt S, Lewinter M M, Hermanovich J, Venkataraman K, Freedman D
Br J Clin Pharmacol. 1985;20 Suppl 1(Suppl 1):178S-186S. doi: 10.1111/j.1365-2125.1985.tb05162.x.
Nicardipine, 30 and 40 mg thrice daily, was administered to 66 patients with stable angina pectoris in a multicentre, randomised, double-blind, cross-over trial. With nicardipine therapy, duration of exercise and cumulative oxygen consumption increased, while times to onset of angina and 1 mm ST segment depression were prolonged. Anginal frequency and nitroglycerin consumption declined with use of nicardipine, but this did not reach statistical significance. Resting heart rate increased slightly and resting blood pressure decreased. Two patients on nicardipine and one on placebo sustained acute infarction. Otherwise, side effects were generally mild and transient.
在一项多中心、随机、双盲、交叉试验中,给66例稳定型心绞痛患者每日三次服用30毫克和40毫克的尼卡地平。采用尼卡地平治疗时,运动持续时间和累积耗氧量增加,而心绞痛发作时间和ST段压低1毫米的时间延长。使用尼卡地平时心绞痛发作频率和硝酸甘油消耗量下降,但未达到统计学显著性。静息心率略有增加,静息血压下降。两名服用尼卡地平的患者和一名服用安慰剂的患者发生急性梗死。否则,副作用一般较轻且为短暂性。